Phenotype frequency of human leukocyte antigens in Japanese patients with renal cell carcinoma who responded to interferon-α treatment

International Journal of Urology

Volumn 3, Issue 6, 1996, Pages 435-440

  Onishi, Tetsuro ^a   Ohishi, Yukihiko ^a   Iizuka, Norio ^a   Imagawa, Kenichi ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Human leukocyte antigens; Interferon ; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; JAPAN; KIDNEY CARCINOMA; MALE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030465249     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00572.x     Document Type: Article

References (16)

1. deKernion JB, Berry D. The diagnosis and treatment of renal cell carcinoma. Cancer 1980;45:1974-1956.
2. Faitlamb DJ. Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 1981;47:2101-2106.
3. Horosezewicz JS, Murphy GP. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989;142:1173-1179.
4. Terasaki PI, Perdue ST, Micket MR. HLA frequencies in cancer: a second study. In: Mulvihill JJ, Miller RW, Faumeni JF (eds) Genetics of human cancer. New York: Raven Press, 1977:321-328.
5. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
6. Bannayan GA, Lamm DL. Renal tumors. Pathol Annu 1980;15:271-308.
7. Back FH, van Rood JJ. The major histocompatibility complex - genetics and biology. N Engl J Med 1976; 295:806-813.
8. Lilly F, Boyse EA, Old LJ. Genetic basis of susceptibility to viral leukaemogenesis. Lancet 1964;2: 1207-1209.
9. Oliver RTD, Pillai A, Klouda PT, Lawler SD. HLA limited resistance in acute myelogenous leukemia. Cancer 1977;39:2337-2341.
10. Kantor AF, Mclaughlin JK, Blattner WA, Bach FH, Blot WJ, Schuman LM, Fraumeni JF Jr. HLA antigens in renal cell carcinoma. Cancer Res 1983;43:2330-2333.
11. Kratzik C, Aiginger P, Kuzmits R, Spona H, Kirnbauer M, Seise A, Mayr WR. HLA-antigen distribution in seminoma, HCG-positive seminoma and non-seminomatous tumors of the testis. Urol Res 1989; 17:377-380.
12. Eryigit M, Kirkali A. HLA antigens and transitional cell carcinoma of the bladder. Urol Int 1990;45:75-77.
13. Marumo K, Hagiwara M, Deguchi N, Jitsukawa S, Murai M, Nakazono M, Tazaki H. Clinical evaluation of interferon against advanced urological cancer. In: Proceedings of the Seventy-seventh Annual Meeting of American Urological Association. Kansas City, Missouri, USA, May 16-20, 1982:165.
14. Bavinck JNB, Kootte AMM, Van Der Woude FJ, Vandenbrouckr JP, Vermeer BJ, Class HJ. On a possible protective effect of HLA-A11 against skin cancer and keratotic skin lesions in renal transplant recipients. J Invest Dermatol 1991;97:269-272.
15. Oliver RTD, Stephenson CA, Parkinson MC, Forman D, Atkinson A, Bodmer J, Bodmer WJ. Hypothesis. Germ cell tumors of the testicle. A model for MHC influence on human malignancy. J Immunol 1986; 13:85-92.
16. + T lymphocytes. Immunol Today 1988;9:268-274.